Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology
SALT LAKE CITY, Jan. 30, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine […]
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood
New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women
Nearly three out of four women falsely believe a pap smear will reveal ovarian cancer presence
Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work
Myriad Genetics announced Great Place To Work® and Fortune magazine have named Myriad Genetics to the 2023 Fortune Best Workplaces in Health Care™ List.
Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1
Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status
Myriad Genetics announced enhancements to the GeneSight® Psychotropic test.
